

**18:00 - 19:30 Opening Ceremony**

Hall A

Chairpersons: **J. Redon, Spain**  
**T. Rosenthal, Israel**

---

Opening Address

**History of University of Valencia**

E.J. Morcillo (*Spain*)

**Position of the EMEA in FDC**

L. Forslund (*Sweden*)

---

**19:30 - 21:00 Welcome Reception**

Exhibition Area

---

**07:00 - 07:50 Free Communications**

Hall B

Chairperson: **E. Paran, Israel**

---

**Effects of Combined Metformin, Glibenclamide and Honey Supplementation on Free Radical Scavenging Enzymes and Lipid Peroxidation in Pancreas of Streptozotocin-Induced Diabetic Rats**

O.O. Erejuwa, S.A. Sulaiman, M.S. Ab Wahab, K.N.S. Sirajudeen, S. Salzihan (*Malaysia*)

**The Effect of Adding Non-Pharmacologic Treatment to Standard Antihypertensive Drug Regimen in Treated but Uncontrolled Hypertensive Patients**

E. Paran, Y. Sharoni, Y. Levi, V. Novack (*Israel*)

**Differences Between Olmesartan/Amlodipine and Olmesartan/Thiazide Combinations on Central Arterial Pressure and Augmentation Index**

A. Otohima, S. Nishihara, M. Nakamura (*Japan*)

**Any-Cause Hospitalization Outcomes Associated with Poor Patient Adherence to Antihypertensives**

J. LaFleur<sup>1</sup>, R. Nelson<sup>1</sup>, B. Sauer<sup>1</sup>, X. Sheng<sup>1</sup>, S. Pickard<sup>1</sup>, S.H. Ong<sup>2</sup>, D. Brixner<sup>1</sup>, J. Nebeker<sup>1</sup>

<sup>1</sup> USA, <sup>2</sup> Switzerland

---

**08:00 - 09:30 Plenary Session 1 (Unrestricted Educational Grant by Boehringer Ingelheim)**

Hall A

Chairpersons: **J.L. Gorriz, Spain**

**K. Narkiewicz, Poland**

---

**History of Fixed Combination**

T. Rosenthal<sup>1</sup>, I. Gavras<sup>2</sup>

<sup>1</sup> Israel, <sup>2</sup> USA

**What is the Best Combination Treatment for Hypertension to Prevent Disease Based on Our Randomised Clinical Trials?**

S.E. Kjeldsen (*Norway*)

**Fixed Combination Therapy: Pluses and Minuses**

M.H. Alderman (*USA*)

**Beneficial Impact of Treating Blood Pressure and Cholesterol Together**

P. Sever (*UK*)

---

**09:30 - 11:00 Satellite Symposium Sponsored by Daiichi Sankyo Europe and Menarini International: Cutting through the Crisis in Hypertension**

Hall A

Chairpersons: **S. Laurent, France**

**J. Redon, Spain**

---

**Introduction**

S. Laurent (*France*)

**The Crisis in Hypertension: Passing the Impasse**

J. Redon (*Spain*)

---

---

**09:30 - 11:00** **Satellite Symposium Sponsored by Daiichi Sankyo Europe and Menarini International: Cutting through the Crisis in Hypertension (Cont.)** Hall A

---

**It's All about the Right Combination**

R. Kreutz (*Germany*)

**24-Hour Control: Olmesartan/Amlodipine Study Results**

G. Parati (*Italy*)

**Beyond BP Lowering in Metabolic Syndrome: The OLAS Study**

F.J. Martinez-Martin (*Spain*)

**Summary and Conclusions**

S. Laurent (*France*)

---

**11:00 - 11:30** **Coffee Break, Exhibition Visit and Poster View** Exhibition Area

---

**11:30 - 13:00** **Plenary Session 2** Hall A  
Chairpersons: **H. Brunner, Switzerland**  
**J.M. Pascual, Spain**

---

**Do We Control the Risk of Hypertension and Peripheral Artery Disease?**

D. Clement (*Belgium*)

**ABPM to Refine the Risk Assessment in Hypertension**

C. Farsang (*Hungary*)

**Position of the Guidelines for Antihypertensive Treatment about FDC**

G. Mancia (*Italy*)

**Treatment of Resistant Hypertension**

S. Oparil, M.C. Acelajado (*USA*)

---

**13:00 - 14:30** **Lunch Break** Exhibition Area

---

**13:00 - 14:30** **Lunchtime Workshop 1 Sponsored by Recordati: New Perspectives in the Hypertension Treatment. Can the CCBs Replace the Diuretics in Combination Treatment?** Hall B  
Chairperson: **G. Parati, Italy**

---

**Welcome**

G. Parati (*Italy*)

**Are All the Antihypertensive Combinations Equipotent?**

S. Erdine (*Turkey*)

**Cardiometabolic Prevention from RAAS Inhibitors Combined with Calcium Channel Blocker**

C. Ferri (*Italy*)

---

---

**13:00 - 14:30 Lunchtime Workshop 1 Sponsored by Recordati: New Perspectives in the Hypertension Treatment. Can the CCBs Replace the Diuretics in Combination Treatment? (Cont.)** Hall B

---

**Second Line Therapy in Type II Diabetes: ACE/ARBS Plus Diuretics or ACE/ARBS Plus CCBs?**

A.J. Manolis

*Greece, USA*

**Discussion**

**Closing Remarks**

G. Parati (*Italy*)

---

**13:00 - 14:30 Lunchtime Workshop 2 Sponsored by Novartis: Hypertension and Health Policy** Hall C  
Chairperson: **L.M. Ruilope, Spain**

---

**Opening Remarks**

L.M. Ruilope (*Spain*)

**Health and Economic Burden of Hypertension**

M. Burnier (*Switzerland*)

**High Blood Pressure and Health Policy: Where We Are and Where We Need to Go Next**

J. Ostergren (*Sweden*)

**Driving Action at the National Level: Spanish Call to Action**

L.M. Ruilope, M. Yarza (*Spain*)

**Panel Discussion**

---

**14:30 - 16:00 Satellite Symposium Sponsored by Pfizer: Managing Cardiovascular Disease: Time is of the Essence** Hall A  
Chairperson: **J. Redon, Spain**

---

**Chair's Welcome and Introduction**

J. Redon (*Spain*)

**The Molecular Basis for Combining Atorvastatin and Amlodipine in a Single Pill: More than Improving Patient Adherence**

P. Mason (*USA*)

**Patient Scenario 1**

P. Mason (*USA*)

**From Test Tubes to Trials: Clinical Evidence for Combining Atorvastatin and Amlodipine in a Single Pill**

P. Sever (*UK*)

---

---

**14:30 - 16:00**   **Satellite Symposium Sponsored by Pfizer: Managing Cardiovascular Disease: Time is of the Essence (Cont.)**   Hall A

---

**Patient Scenario 2**

P. Mason (*USA*)

**Amlodipine and Atorvastatin in a Single Pill: Use in Clinical Practice**

A. Pathak (*France*)

**Patient Scenario 3**

P. Mason (*USA*)

**Close**

J. Redon (*Spain*)

---

**16:00 - 16:30**   **Coffee Break, Exhibition Visit and Poster View**   Exhibition Area

---

**16:30 - 18:00**   **Plenary Session 3 (Supported by Novartis)**   Hall A  
Chairpersons: **K. Kostner, Australia**  
**A. Salvetti, Italy**

---

**Has the Time Come for a Fixed Combination of Renin Inhibitor with ACEI or ARB?**

H. Gavras (*USA*)

**Impact of Different Fixed Drug Combinations in the 24-Hour Blood Pressure Circadian Profile**

M. Bursztyn (*Israel*)

**Firstline Combination Therapy in Hypertension - When, How and What?**

F.H. Messerli (*USA*)

**Molecular Basis of Vascular Protection by Combination Therapy**

H. Haller (*Germany*)

---

**08:00 - 09:30 Plenary Session 4 (Supported by Daiichi Sankyo Europe and Menarini International) Hall A**

Chairpersons: **J. Rodicio, Spain**  
**E. Holtzman, Israel**

---

**What is the Future for the Polypill?**

R. Grimm (*USA*)

**The Polypill: Critical Evaluation of Rationale, Expectations and First Results**

T. Unger (*Germany*)

**Raas Inhibition and Renoprotection - Are They Doing it Beyond Blood Pressure Lowering**

L.M. Ruilope (*Spain*)

**Combination Therapy for Total Blockade of the Renin-Angiotensin-Aldosterone Blockade**

A. Mimran (*France*)

---

**09:30 - 11:00 Satellite Symposium Sponsored by Novartis: Single-Pill Combinations in the Management of Hypertension and CV Risks Hall A**

Chairperson: **J. Redon, Spain**

---

**Opening Remarks**

J. Redon (*Spain*)

**The True Costs of High Blood Pressure**

M. Burnier (*Switzerland*)

**Advancing Care with Single-Pill Combination: What Are the Benefits?**

J. Redon (*Spain*)

**The RAAS: A Foundation for Antihypertensive Combination Therapy**

B. Dahlöf (*Sweden*)

**Innovations in Antihypertensive Therapy through Direct Renin Inhibition**

R. Dusing (*Germany*)

**Panel Discussion**

---

**11:00 - 11:30 Coffee Break, Exhibition Visit and Poster View Exhibition Area**

---

**11:30 - 13:00 Plenary Session 5 Hall A**

Chairpersons: **S. Erdine, Turkey**  
**H. Ibsen, Denmark**

---

**Can We Manipulate Adipose Tissue, Independent of Weight Loss, to Improve the Metabolic Syndrome?**

N. Stern (*Israel*)

---

**11:30 - 13:00 Plenary Session 5 (Cont.)**

Hall A

**Can We Prevent Diabetes in Patients with the Metabolic Syndrome? New Pharmacological Avenues and Potential Combination Therapy**

S. Del Prato (*Italy*)

**Risk Factor Control in Diabetes - New Directions Based on Fixed Drug Combinations**

P. Nilsson (*Sweden*)

---

**13:00 - 14:30 Lunchtime Workshop 3**

Hall B

Chairpersons: **H. Gavras, USA**

**Y. Seedat, South Africa**

---

**Blood Pressure Control in Eastern European Countries**

S. Torbova (*Bulgaria*)

**Advances in The Treatment of Fixed Drug Combination in Hypertension and Hyperlipidaemia in Low and Middle Income Countries**

Y. Seedat (*South Africa*)

**Patients' Adherence to Treatment**

P.W. De Leeuw (*The Netherlands*)

**Early CV Risk Phenotype in Obese Adolescents**

E. Lurbe (*Spain*)

---

**13:00 - 14:30 Lunchtime Workshop 4**

Hall C

Chairpersons: **F. Messerli, USA**

**P. Sever, UK**

---

**Arterial Properties and Combination Therapy**

R. Zimlichman (*Israel*)

**Current Treatment Combination Strategies in High Risk Hypertensive Patients**

A. Coca (*Spain*)

**Differential Effect of Sartans with Various PPAR ; Activating Capacity Combined with Statin on Glucose Metabolism Indices**

M.S. Elisaf (*Greece*)

---

**14:30 - 16:00 Plenary Session 6**

Hall A

Chairpersons: **A. Januszewicz, Poland**

**A.J. Manolis, Greece**

---

**Tablet Load in Hypertensive Patients**

D.G. Beevers (*UK*)

**Treatment Goals in Patients with Hypertension**

K.H. Rahn (*Germany*)

---

**14:30 - 16:00 Plenary Session 6 (Cont.)**

Hall A

**Is There Still Room for Individualized Antihypertensive Therapy Using Fixed Drug Combinations?**

B. Waeber (*Switzerland*)

**Hypertension and Atrial Fibrillation**

A.J. Manolis

*Greece, USA*

---

**16:00 - 16:30 Coffee Break, Exhibition Visit and Poster View**

Exhibition Area

---

**16:30 - 17:30 Panel Discussion: Pros and Cons of Fixed Combinations under Various Healthcare Systems**

Hall A

Chairperson: **A. Zanchetti**, Italy

Panelists:

I. Gavras, USA

F. Messerli, USA

S. Oparil, USA

K.H. Rahn, Germany

B. Waeber, Switzerland

J. Weissgarten, Israel

---

**17:30 - 18:00 Closing Ceremony**

Hall A

---

- 1 **Effect on Ambulatory Blood Pressure of a Fixed Combination of ACE Inhibitor and Calcium Channels Blocker (Dironorm) Added to Pre-Existence Antihypertensive Therapy in Uncontrolled High Risk Hypertensive Patients**  
D. Raev, T. Yanev, S. Torbova (*Bulgaria*)
- 2 **Effect of a Fixed Combination ACE Inhibitor and Calcium Channel Blocker (Dironorm) on Central Blood Pressure and Aortic Stiffness in Untreated Hypertensive Patients**  
D. Raev, A. Staneva (*Bulgaria*)
- 3 **Effect of a Fixed Combination ACE Inhibitor and Calcium Channel Blocker (Dironorm) on Endothelial Function in Untreated Hypertensive Patients**  
D. Raev, I. Ivanov (*Bulgaria*)
- 4 **Evaluation of the Efficacy and Tolerability of Fixed-Dose Combination of Lisinopril and Amlodipine in the Treatment of Uncontrolled High-Risk Hypertensive Patients**  
S. Torbova, D. Raev, L. Vladimirova, S. Naydenov, G. Gentchev (*Bulgaria*)
- 5 **Treatment Experience of Ezitimibe and Metformine at Patients with Non-Alcoholic Fatty Liver Disease**  
E. Egorova, L. Zvenigorodskaya, N. Melnikova, S. Chomeriki (*Russia*)
- 6 **Effects of Combined Metformin and Honey Supplementation on Antioxidant Enzymes and Markers of Oxidative Stress in Kidneys of Streptozotocin-Induced Diabetic Rats**  
O.O. Erejuwa, S.A. Sulaiman, M.S. Ab Wahab, K.N.S. Sirajudeen, S. Salzihan (*Malaysia*)
- 7 **The Efficacy of a Fixed Combination Amlodipine - Valsartan in the Control of Moderate - Severe Essential Hypertension**  
C. Zorila, L. Mos, A. Wiener, A. Marian (*Romania*)
- 8 **The Kalium Balance in Elderly Hypertensive Patients Treated with Quinaprilum-Hydrochlorothiazide Combination**  
L. Mos, C. Zorila, A. Wiener, A. Marian (*Romania*)
- 9 **The Change of Left Ventricle Diastolic Function in the Patients with Type 2 Diabetes and Arterial Hypertension**  
G. Abuladze, N. Jinjolia, S. Tvaltchrelidze (*Georgia*)
- 10 **Fixed Dose Combination Drugs for Hypertension, Diabetes Mellitus and Dyslipidemia - How Relevant to the Nigerian Black Population?**  
O. Ogunleye, S. Ogundele, A. Ogbera (*Nigeria*)
- 11 **The Coexistence of Coronary-Pulmonary Fistula, Diabetes Mellitus and Subacute Cutaneus lupus Erythematosus, Case Study**  
B. Przywara, M. Pindycka-Piaszczyńska, M. Paluch, M. Opara, M. Pluszczyk, D. Kawecki, J. Dola, M. Fudal, A. Tomasik, A. Kuczaj, E. Nowalany-Kozielska  
*Poland*

Posters (Cont.)	Exhibition Area
12 <b>Lipid Profile Under Treatment in Diabetes</b> <u>S. Bistriceanu</u> ( <i>Romania</i> )	
13 <b>Lipid Profile Under Treatment in Type 2 Diabetes</b> <u>S. Bistriceanu</u> ( <i>Romania</i> )	
14 <b>Reduction in Blood Pressure and Low-Density Lipoprotein Cholesterol When Single-Pill Amlodipine/Atorvastatin is Used as First-Line or Add-On Treatment</b> <u>J. Flack</u> <sup>1</sup> , <u>R. Feldman</u> <sup>2</sup> , <u>R. Hobbs</u> <sup>3</sup> , <u>L. Howes</u> <sup>4</sup> , <u>T. Jenssen</u> <sup>5</sup> , <u>R. Reeves</u> <sup>1</sup> , <u>R. Moller</u> <sup>1</sup> , <u>H. Shi</u> <sup>1</sup> , <u>M. Westergaard</u> <sup>1</sup> <sup>1</sup> USA, <sup>2</sup> Canada, <sup>3</sup> UK, <sup>4</sup> Australia, <sup>5</sup> Norway	
15 <b>A Comparison of Blood Pressure and Low-Density Lipoprotein Cholesterol Reduction After Treatment With Single-Pill Amlodipine/Atorvastatin in Elderly (75 years or more) and Younger (less than 75 years) Patients: Results of a Pooled Analysis of 5559 Patients</b> <u>R. Feldman</u> <sup>1</sup> , <u>J. Flack</u> <sup>2</sup> , <u>R. Hobbs</u> <sup>3</sup> , <u>L. Howes</u> <sup>4</sup> , <u>T. Jenssen</u> <sup>5</sup> , <u>R. Reeves</u> <sup>2</sup> , <u>H. Shi</u> <sup>2</sup> , <u>M. Westergaard</u> <sup>2</sup> <sup>1</sup> Canada, <sup>2</sup> USA, <sup>3</sup> UK, <sup>4</sup> Australia, <sup>5</sup> Norway	
16 <b>A Comparison of Blood Pressure and Low-Density Lipoprotein Cholesterol Reduction After Treatment With Single-Pill Amlodipine/Atorvastatin in Younger (Less Than 65 Years) and Older (65 Years or More) Men and Women: Results of a Pooled Analysis of 5559 Patients</b> <u>R. Hobbs</u> <sup>1</sup> , <u>R. Feldman</u> <sup>2</sup> , <u>J. Flack</u> <sup>3</sup> , <u>L. Howes</u> <sup>4</sup> , <u>T. Jenssen</u> <sup>5</sup> , <u>R. Reeves</u> <sup>3</sup> , <u>H. Shi</u> <sup>3</sup> , <u>M. Westergaard</u> <sup>3</sup> <sup>1</sup> UK, <sup>2</sup> Canada, <sup>3</sup> USA, <sup>4</sup> Australia, <sup>5</sup> Norway	
17 <b>Efficacy of the Combination of Lisinopril and Hydrochlorothiazide in Patients with Hypertension and Metabolic Syndrome Uncontrolled with Previous Treatment</b> <u>N.I. Stolyarova</u> , <u>E.D. Li</u> , <u>T.V. Boriskina</u> ( <i>Russia</i> )	
18 <b>Dyslipidemia and Arterial Hypertension in Patients with Diabetes Mellitus and Erectile Dysfunction Involve a Predominant Pro-Inflammatory Background</b> <u>M.d.J. Arana Rosainz</u> , <u>M. Ojeda</u> , <u>R. Fragas Valdes</u> , <u>C.T. Garcia Alvarez</u> , <u>L. Castelo Elias-Calles</u> , <u>N. Orlandi</u> , <u>O. Torres</u> , <u>E. Maciquez</u> , <u>M. Estevez</u> <i>Cuba</i>	
19 <b>Telmisartan in Combination with Amlodipine Provides a Highly Effective and Well Tolerated Treatment Option for Hypertensive Patients with Diabetes: Sub-Analysis from a Factorial Design Study</b> <u>T. Littlejohn</u> <sup>1</sup> , <u>L. Ruilope</u> <sup>2</sup> , <u>P. Raskin</u> <sup>1</sup> , <u>J. Neutel</u> <sup>1</sup> , <u>C. Majul</u> <sup>3</sup> , <u>W. Oigman</u> <sup>4</sup> , <u>R. Olvera</u> <sup>5</sup> , <u>M. Seeber</u> <sup>6</sup> , <u>M. Kobe</u> <sup>1</sup> , <u>H. Schumacher</u> <sup>7</sup> <sup>1</sup> USA, <sup>2</sup> Spain, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany	

- 20 **Combination of Telmisartan with Amlodipine Provides an Effective Treatment Option for Elderly Patients: Sub-Analysis from a Factorial Design Study**  
T. Littlejohn<sup>1</sup>, B. Dahlof<sup>2</sup>, S. Chrysant<sup>1</sup>, J. Neutel<sup>1</sup>, C. Majul<sup>3</sup>, W. Oigman<sup>4</sup>, R. Olvera<sup>5</sup>, M. Seeber<sup>6</sup>, M. Kobe<sup>1</sup>, H. Schumacher<sup>7</sup>  
<sup>1</sup> USA, <sup>2</sup> Sweden, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany
- 21 **Telmisartan and Amlodipine in Combination are Effective at Lowering 24-Hour BP in Elderly Hypertensive Patients and Those With Elevated SBP: Findings of an ABPM Sub-Study**  
T. Littlejohn<sup>1</sup>, G. Mancia<sup>2</sup>, R. Christensen<sup>1</sup>, R. Guthrie<sup>1</sup>, C. Majul<sup>3</sup>, W. Oigman<sup>4</sup>, R. Olvera<sup>5</sup>, M. Seeber<sup>6</sup>, M. Kobe<sup>1</sup>, H. Schumacher<sup>7</sup>  
<sup>1</sup> USA, <sup>2</sup> Italy, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany
- 22 **Telmisartan and Amlodipine in Combination are Effective at Lowering 24-Hour BP in Diabetic and Obese Hypertensive Patients: Findings of an ABPM Sub-Study**  
T. Littlejohn<sup>1</sup>, G. Mancia<sup>2</sup>, R. Guthrie<sup>1</sup>, R. Marple<sup>1</sup>, C. Majul<sup>3</sup>, W. Oigman<sup>4</sup>, R. Olvera<sup>5</sup>, M. Seeber<sup>6</sup>, M. Kobe<sup>1</sup>, H. Schumacher<sup>7</sup>  
<sup>1</sup> USA, <sup>2</sup> Italy, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany
- 23 **Efficacy of Telmisartan in Combination with Amlodipine in Obese Hypertensive Patients: Sub-Analysis from a Factorial Design Study**  
T. Littlejohn<sup>1</sup>, L. Ruilope<sup>2</sup>, S. Chrysant<sup>1</sup>, D. Webster<sup>1</sup>, C. Majul<sup>3</sup>, W. Oigman<sup>4</sup>, R. Olvera<sup>5</sup>, M. Seeber<sup>6</sup>, M. Kobe<sup>1</sup>, H. Schumacher<sup>7</sup>  
<sup>1</sup> USA, <sup>2</sup> Spain, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany
- 24 **Telmisartan and Amlodipine in Combination Provide an Effective Treatment Option for Patients with Elevated Systolic BP: Sub-Analysis from a Factorial Design Study**  
T. Littlejohn<sup>1</sup>, B. Dahlof<sup>2</sup>, S. Chrysant<sup>1</sup>, J. Neutel<sup>1</sup>, C. Majul<sup>3</sup>, W. Oigman<sup>4</sup>, R. Olvera<sup>5</sup>, M. Seeber<sup>6</sup>, M. Kobe<sup>1</sup>, H. Schumacher<sup>7</sup>  
<sup>1</sup> USA, <sup>2</sup> Sweden, <sup>3</sup> Argentina, <sup>4</sup> Brasil, <sup>5</sup> Mexico, <sup>6</sup> South Africa, <sup>7</sup> Germany
- 25 **Fixed-Dose Combination Therapy with Telmisartan and Amlodipine 5 Mg in Non-Responders to Amlodipine 5 Mg Provides Superior Blood Pressure Reductions to, and is Better Tolerated than, Amlodipine 10 Mg**  
S. Neldam<sup>1</sup>, M. Lang<sup>2</sup>  
<sup>1</sup> Denmark, <sup>2</sup> The Netherlands
- 26 **Hypertension Prevalence, Awareness, Treatment, and Control in Yazd, Iran**  
Z. Kalani, H. Abdi, L. Shahbazi, T. Salimi, M.R. Aminipour, P. Pourmovahed (*Iran*)
- 27 **Regulations of Fixed Dose Combinations of Antidiabetic Drugs: A Comparative Study**  
S. Dharmagadda, M. Janodia, V. Ligade, U. Nayanabhirama (*India*)
- 28 **Oxidative Stress and eNOS(Glu298Asp) Gene Polymorphism in Pre-Eclampsia- in Indian Population**  
D. Sharma, A. Singh, S.S. Trivedi, J. Bhattacharjee (*India*)

---

Posters (Cont.)	Exhibition Area
29	<b>Efficacy and Safety of Single-Pill Amlodipine/Atorvastatin for the Reduction of Cardiovascular Risk in Slovakia: The STRONG DUET Study</b> <u>D. Pella</u> , J. Fedacko, R. Rybar ( <i>Slovakia</i> )
30	<b>Olmesartan Medoxomil/Amlodipine (OLM/AML) Provides 24-Hour Antihypertensive Efficacy - Additional Effect by Uptitration in Patients with Moderate-to-Severe Hypertension</b> A. Heagerty <sup>1</sup> , <u>P. Laeis</u> <sup>2</sup> , U. Haag <sup>2</sup> <sup>1</sup> UK, <sup>2</sup> Germany
31	<b>Development of Fingertip Microangiography using Synchrotron Radiation to Determine Fixed Combination in the Treatment of Metabolic Syndrome</b> <u>H. Mori</u> , T. Fujii, N. Fukuyama, Y. Ikeya, Y. Shinozaki, K. Umetani, T. Tanabe ( <i>Japan</i> )
32	<b>Olmesartan Plus Amlodipine Improve Metabolic and Inflammation Markers in Hypertensive Patients with Metabolic Syndrome: the OLAS Study</b> <u>F.J. Martinez Martin</u> , C. Comi-Diaz, P. Pedrianes-Martin, H. Rodriguez-Rosas, I. Peiro-Martinez, P. Soriano-Perera <i>Spain</i>
33	<b>Dose Dependence of the Metabolic and Inflammation Marker Changes with Olmesartan/Amlodipine and Olmesartan/Hydrochlorothiazide in the OLAS Study</b> <u>F.J. Martinez Martin</u> , C. Comi-Diaz, P. Pedrianes-Martin, H. Rodriguez-Rosas, I. Peiro-Martinez, P. Soriano-Perera <i>Spain</i>
34	<b>Hypotensive and Renoprotective Effect and Possible Deteriorative Effect on Glycemic Control of Fixed Combination of Losartan and Hydrochlorothiazide in Japanese Type 2 Diabetic Patients with Hypertension</b> <u>Y. Hamamoto</u> , H. Ikeda, S. Honjo, Y. Kawasaki, K. Nomura, Y. Iwasaki, Y. Wada, H. Koshiyama <i>Japan</i>
35	<b>Olmesartan Medoxomil/Amlodipine (OLM/AML) Improves Blood Pressure Control Throughout 24 Hours as Compared to AML Monotherapy in Patients with Moderate-to-Severe Hypertension</b> <u>G. Parati</u> , G. Bilo ( <i>Italy</i> )
36	<b>Therapeutic Potential of Dietary Phase 2 Enzyme Inducer in Hypertension</b> <u>A. Banigesh</u> , V. Senanyake, L. Wu, P. Lee, K. Desai, B. Juurlink ( <i>Canada</i> )

---